Skip to main content
OpenTrials
Completed

NCT Number: NCT02588313

Investigation of Long-term Effects of CarelessTM on Microcirculation

Aim of the study is to investigate long-term effects of CarelessTM, a Mangifera indica fruit powder on microcirculation and endothelial function after supplementation of 4 weeks. Effects will be investigated with 100mg and 300mg CarelessTM and compared to placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

BioTeSys GmbH

Esslingen am Neckar, 73728, Germany

About this study

Aim of the study is to investigate long-term effects of CarelessTM, a Mangifera indica fruit powder on microcirculation and endothelial function after supplementation of 4 weeks. Effects will be investigated with 100mg and 300mg CarelessTM and compared to placebo.

To describe targeted parameter, cutaneous microcirculation will be measured at 1 mm depth as well as flow mediated endothelial function at the beginning and end of supplementation, each. Furthermore, the parameters will be determined postprandially 1 hour after glucose loading. Additionally the influence on the glucose metabolism, as well as on body weight and body fat will be documented.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Men and postmenopausal women
  • HOMA Index ≥2 and <5
  • BMI: 19 - 30 kg/m2
  • Age ≥ 40 and ≤ 70 years
  • Nonsmoker
  • Written consent to participate in the study
  • Able and willing to follow the study protocol procedures

Exclusion criteria

  • Relevant history, presence of any medical disorder or chronic intake of medication/dietary sup-plements (e.g. polyphenols, L-Arginine, Niacin, medication of haemodilution, blood flow stimu-lating products like Aspirin (Acetylsalicylsäure), Clopidogrel (Adenosin-Diphosphat(ADP)-Inhibitors), Glykoprotein-IIb/IIIa-Inhibitors, Heparin, Marcumar (Vitamin K antagonists); Dabiga-tran (Faktor IIa synthese Inhibitors) Rivaroxaban (Faktor Xa Antagonist), Statins) potentially in-terfering with this study at screening.
  • For this study clinically relevant abnormal laboratory, vital signs or physical findings at screening
  • Diabetes
  • Atopic dermatitis or affected skin at the forearm
  • Injury on the finger, influencing the EndoPATTM measurement
  • Regular consumption of caffeine > 275 mg (equivalent to 3-4 cups of coffee or 9 cups of black tea)
  • Change of dietary habits within the 2 weeks prior to screening (for instance start of a diet high in vegetables and fruits (≥ 5 portions per day))
  • Diet high in vegetables and fruits ≥ 5 portions per day
  • Participants anticipating a change in their lifestyle or physical activity levels during the study.
  • Subjects not willing to avoid polyphenol rich foods and abstain from beverages containing caf-feine the day prior to visit 1 and 2.
  • Subjects not willing to abstain from intake of analgesic medication (e.g. Aspirin) 24 hours prior to and during visit 1 and 2.
  • Sunbathing or the use of sun-beds 2 weeks prior to study days
  • Subjects with history of drug, alcohol or other substances abuse, or other factors limiting their ability to co-operate during the study.
  • Known hypersensitivity to the study preparation or to single ingredients
  • Pregnant subject or subject planning to become pregnant during the study; breast-feeding sub-ject.
  • Known HIV-infection
  • Known acute or chronic hepatitis B and C infection
  • Blood donation within 4 weeks prior to visit 1 or during the study.
  • Subject involved in any clinical or food study within the preceding month

Treatment and study plan

Mango fruit powder

Dietary Supplement

Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design

Other names: CarelessTM

Primary outcomes

  1. Measurement of circulation

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Measurement of dermal microcirculation using "O2C, Lea Technik":

    • Relative peripheral blood flow (LDF)
    • Venous oxygen saturation (SO2 ven)
    • Relative amount of haemoglobin (rHb). Delta change of dermal microcirculation from baseline to end of supplementation is investigated. Addi-tionally, the delta change of dermal microcirculation from baseline to end of supplementation post-prandial is determined, which means the evaluation of postprandial effects on reactive hyperaemia index after glucose load.

Secondary outcomes

  1. Measurement of glucose related biomarker

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Measurement of Biomarker HOMA-Index, HbA1c at baseline and end of supplementation under fasting conditions.

  2. Questionnaire on fatigue and vigor

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Questionnaire on fatigue and vigor

  3. Monitoring of adverse effects

    Time frame: During study execution over 4 weeks

    Reporting of adverse effects to evaluate tolerability

  4. Measurement of endothelial function using "EndoPATTM, Itamar"

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Measurement of endothelial function using "EndoPATTM, Itamar"

    • Reactive hyperaemia index (RHI and lnRHI)
    • Arterial stiffness (AI75) Delta change of endothelial function and arterial stiffness from baseline to end of supplementation is investigated. Additionally, the delta change of endothelial function from baseline to end of supplemen-tation postprandial is determined, which means the evaluation of postprandial effects on relative hy-peraemia index after glucose load.
  5. Measurement of ox LDL

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Measurement of ox LDL

Other outcomes

  1. Body composition

    Time frame: Baseline at day 1 and after 4 weeks supplementation

    Body weight and body fat (Body impedance analysis) determination

  2. Blood glucose

    Time frame: Baseline at day 1 and after 4 weeks supplementation, before 1h and 2h after glucose loading

    Capillary blood glucose

Sponsors and collaborators

Lead sponsor

Vital Solutions Swiss AG

Industry

Registry information

Official study title

Investigation of Long-term Effects of CarelessTM on Microcirculation in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Oct 27, 2015
Registry last updated
Sep 23, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.